PharmAccess mobilizes public and private resources for the benefit of doctors and patients through clinical standards and quality improvements, loans for healthcare providers, health insurance, mHealth innovations and operational research.
On behalf of PharmAccess and more specifically the The PharmAccess African Studies to Evaluate Resistance (PASER) program, Dr. Raph Hamers and Dr Nicaise Ndembi both held an oral presentation at the prestigious 18th Conference on Retroviruses and Opportunistic Infections (CROI).
On behalf of PharmAccess and more specifically the The PharmAccess African Studies to Evaluate Resistance (PASER) program, Dr. Raph Hamers and Dr Nicaise Ndembi both held an oral presentation at the prestigious 18th Conference on Retroviruses and Opportunistic Infections (CROI), held in Boston, Massachusetts from February 27 through March 2. The PASER results presented were received with great interest. CROI is a scientifically focused meeting of the world’s leading researchers working to understand, prevent, and treat HIV/AIDS and its complications. The goal of CROI is to provide a forum for translating laboratory and clinical research into progress against the AIDS epidemic.
PASER is an ambitious and large-scale capacity building and research program. PASER aims to establish a network of clinical sites and laboratories in 6 countries in sub-Saharan Africa, in order to build capacity for the monitoring and surveillance of HIV drug resistance. The research outcomes of this ‘early warning system’ will provide unique information on HIV drug resistance patterns in Africa.
